Sciwind Biosciences Reports Positive Interim Results from Phase 1c/2a Clinical Trial of XW003 (Ecnoglutide) in Overweight and Obese Adult Volunteers in China ...Middle East

PR Newswire - News
Sciwind Biosciences Reports Positive Interim Results from Phase 1c/2a Clinical Trial of XW003 (Ecnoglutide) in Overweight and Obese Adult Volunteers in China
Mean body weight loss of 9.6% and 9.0% in participants receiving 1.8 mg and 2.4 mg XW003 for 14 weeks, respectively Up to 72.4% of participants achieved weight loss of at least 5% at week 14 XW003 was safe and well tolerated with gastrointestinal side effects as the most commonly reported...

Hence then, the article about sciwind biosciences reports positive interim results from phase 1c 2a clinical trial of xw003 ecnoglutide in overweight and obese adult volunteers in china was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Sciwind Biosciences Reports Positive Interim Results from Phase 1c/2a Clinical Trial of XW003 (Ecnoglutide) in Overweight and Obese Adult Volunteers in China )

Apple Storegoogle play

Last updated :

Also on site :